145 new news items in the last 24 hours

22 September 14:14

Pfizer buys Metsera to expand its portfolio in the field of obesity drugs, paying 4.9 billion dollars

Cristina Petrache

main event image

Economy

Foto DW labs Incorporated / Shutterstock.com

By acquiring Metsera, Pfizer aims to engage in the expanding market of obesity medications, paying $47.50 per share, with bonuses tied to clinical objectives. Metsera develops innovative treatments for obesity and cardiometabolic diseases, having promising candidates in its portfolio. The transaction, approved by the boards of directors, will be finalized by the end of 2025, pending necessary approvals. This will allow Pfizer to compete with current market leaders, such as Novo Nordisk and Eli Lilly.

Sources

Pfizer va cumpăra producătorul de medicamente pentru obezitate Metsera pentru 4,9 miliarde de dolari

Business Magazin

Pfizer va cumpăra producătorul de medicamente pentru obezitate Metsera pentru 4,9 miliarde de dolari

independent.co.uk

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer își extinde portofoliul: Gigantul farmaceutic cumpără producătorul de medicamente pentru obezitate Metsera

Pfizer, aproape să finalizeze achiziţia grupului Metsera pentru 7,3 miliarde de dolari - Financial Times

ȘTIRI PE ACELEAȘI SUBIECTE

International

Pfizer won the auction for the acquisition of Metsera, with a bid of 10 billion dollars, thus ending the competition with Novo Nordisk.

Health

Pfizer has sued Novo Nordisk, accusing it of anti-competitive practices in an attempt to take over Metsera, a potential competitor in the obesity treatment market.

International

Pfizer estimates an adjusted profit of $3-3.15 per share for 2025, but quarterly revenues have decreased by 6% to $16.65 billion

International

The Swiss pharmaceutical company Novartis announced on Sunday the signing of an agreement to acquire the American biotechnology firm Avidity Biosciences for approximately 12 billion dollars.

International

President Trump announced an agreement to reduce the costs of GLP-1 medications, expanding access for Medicare and Medicaid patients.

International

Crisis at the peak of Novo Nordisk, at one point the most valuable European company. The president and several independent directors resign after a conflict with the majority shareholder.

Personalized news feed, AI-powered search, and notifications in a more interactive experience.

Pfizer medically obesity actions health

Personalized news feed, AI-powered search, and notifications in a more interactive experience.

app preview

google play badge